ImmunityBio Inc
IBRX | $5.48 10.93% 9.85% 31M
|
Manufacturing
(0.0% 1d) (0.9% 1m) (133.6% 1y) (0.0% 2d) (4.1% 3d) (11.8% 7d) (Infinity% volume)
Earnings Calendar: 2024-02-29
Market Cap: $ 3,709,978,692
https://immunitybio.com
Sec Filling | Patents | n/a employees
NantKwest (NASDAQ: NK) is an innovative, clinical-stage, immunotherapy company focused on harnessing the power of the innate immune system to treat cancer and infectious diseases. NantKwest is the leading producer of clinical dose forms of off-the-shelf natural killer (NK) cell therapies. The activated NK cell platform is designed to destroy cancer and virally-infected cells. The safety of these optimized, activated NK cells-as well as their activity against a broad range of cancers-has been tested in phase I clinical trials in Canada and Europe, as well as in multiple phase I and II clinical trials in the United States. By leveraging an integrated and extensive genomics and transcriptomics discovery and development engine, together with a pipeline of multiple, clinical-stage, immuno-oncology programs, NantKwest's goal is to transform medicine by bringing novel NK cell-based therapies to routine clinical care. NantKwest is a member of the NantWorks ecosystem of companies.
cancer t-cell infectious disease immunotherapy ceiling injection optical
add to watch list Paper trade email alert is off
Press-releases
ImmunityBio Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Published: 2024-04-23 (Crawled : 07:00) - biospace.com/
IBRX | $5.48 10.93% 9.85% 31M
|
Manufacturing
|
| O: 16.59%
H: 0.65%
C: -10.73%
il-15 anktiva fda agonist approval bladder cancer for
NIAID-Sponsored Study Shows N-803 Combined with Neutralizing Antibodies Could Lead to Sustained HIV Viral Control After Discontinuation of Antiretroviral Therapy
Published: 2024-03-06 (Crawled : 14:30) - immunitybio.com
IBRX | $5.48 10.93% 9.85% 31M
|
Manufacturing
|
| O: 4.15%
H: 2.59%
C: 1.2%
control hiv therapy study
N-803 Combined with Natural Killer Cells Showed Potential to Reduce HIV Viral Load in HIV Positive Subjects; Part of HIV Cure Study
Published: 2024-03-05 (Crawled : 14:30) - immunitybio.com
IBRX | $5.48 10.93% 9.85% 31M
|
Manufacturing
|
| O: -1.38%
H: 6.6%
C: -3.6%
cure natural positive hiv potential study
ImmunityBio Announces Full Accrual of First Two Phases of Cancer Vaccine Trial in Participants with Lynch Syndrome and Initiation of Randomized Controlled Phase of the Trial
Published: 2024-02-21 (Crawled : 15:00) - biospace.com/
IBRX | $5.48 10.93% 9.85% 31M
|
Manufacturing
|
| O: 1.27%
H: 0.31%
C: -2.3%
first vaccine cancer trial
ImmunityBio Quality-of-Life Study in BCG-Unresponsive Bladder Cancer Trial Indicates Improved Physical Function in the 71% Complete Responders Suggesting a Favorable Risk-Benefit Ratio for N-803 Plus BCG
Published: 2024-02-05 (Crawled : 14:30) - immunitybio.com
IBRX | $5.48 10.93% 9.85% 31M
|
Manufacturing
|
| O: -1.93%
H: 1.35%
C: -0.49%
favorable bladder cancer trial plus study
ImmunityBio Announces $320 Million Investment by Oberland Capital, with $210 Million Funded at Closing, Bringing Total Financing in 2023 to $850 Million
Published: 2024-01-02 (Crawled : 12:00) - nantkwest.com
IBRX | $5.48 10.93% 9.85% 31M
|
Manufacturing
|
| O: -0.6%
H: 5.01%
C: 5.01%
million total
ImmunityBio to Participate in 35th Annual Piper Sandler Healthcare Conference
Published: 2023-11-16 (Crawled : 14:30) - nantkwest.com
IBRX | $5.48 10.93% 9.85% 31M
|
Manufacturing
|
| O: 0.98%
H: 2.42%
C: -0.97%
conference
First Data for ImmunityBio’s Memory Cytokine-Enriched NK Cells in Small Cell Lung Cancer at SITC Meeting Show Promising Anti-tumor Activity
Published: 2023-11-07 (Crawled : 15:00) - nantkwest.com
IBRX | $5.48 10.93% 9.85% 31M
|
Manufacturing
|
| O: -0.83%
H: 3.92%
C: 1.68%
lung cancer cell meeting show
FDA Accepts ImmunityBio’s BLA Resubmission as Complete and Sets New PDUFA Date
Published: 2023-10-26 (Crawled : 14:00) - nantkwest.com
IBRX | $5.48 10.93% 9.85% 31M
|
Manufacturing
|
| O: 6.96%
H: 23.67%
C: 21.3%
fda resubmission pdufa
ImmunityBio Announces Biological License Application Resubmission for N-803 in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer Carcinoma-In-Situ
Published: 2023-10-23 (Crawled : 13:30) - biospace.com/
IBRX | $5.48 10.93% 9.85% 31M
|
Manufacturing
|
| O: 7.69%
H: 14.29%
C: 2.14%
resubmission license bladder cancer application
Last 15 days Sec forms
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Last 48 Hours Insiders Buying
MEGI | $11.975 1.87% 0.04% 140K
|
|
00:30
CTRN P 29000 | $22.25 0.14% 0.13% 100K
|
Retail Trade
|
22:00
CONN | $3.71 1.37% 1.35% 72K
|
Retail Trade
|
21:30
TGEN P 6000 | $0.6897 39.71% 2.3K
|
Utilities
|
18:30
CMTV P 700 | $15.74 17.43% 12K
|
Finance and Insurance
|
18:30
FNB | $13.63 2.17% 0.0% 2.5M
|
Finance
|
17:30
RMCF | $3.57 0.28% 2.8K
|
Consumer Non-Durables
|
20:10